# BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

> **NCT06321068** · PHASE2,PHASE3 · TERMINATED · sponsor: **Bio-Thera Solutions** · enrollment: 5 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Recombinant humanized anti-PD-1 monoclonal antibody injection

## Key facts

- **NCT ID:** NCT06321068
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-09
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-08-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06321068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06321068, "BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06321068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*